Sickle cell disease patients who have relatively low pain levels use opioids more when they are sad, anxious, or experience…
Margarida Azevedo, MSc
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Azevedo, MSc
A new online platform, called oneSCDvoice.com, will help those affected by sickle cell disease (SCD) by offering free access to…
Anyah Randolph, a teenager with sickle cell disease (SCD), was recently able to join her school class on a…
An independent review board has found Global Blood Therapeutics’ sickle cell disease treatment voxelotor safe, and recommended that its Phase 3 clinical…
The Medical College of Georgia (MCG) and Augusta University Health (AU Health) have joined the first large, national…
Hydroxyurea, a treatment recommended for children with sickle cell anemia (SCA), doesn’t increase the risk of malaria infection in…
Cydan, the company that founded Imara — which developed a sickle cell disease (SCD) treatment candidate, IMR-687 — has…
The California Institute for Regenerative Medicine (CIRM) awarded Matthew Porteus, a Stanford University associate professor of pediatrics, a $5.2 million grant…
The U.S. Food and Drug Administration (FDA) has awarded Dr. Kenneth Ataga, a $2 million grant over five years to…
Sancilio Pharmaceuticals has completed a Phase 2 clinical trial evaluating Altemia (docosahexaenoic acid) as a treatment for children aged 5…